Author: Don Obrien

Small Biotechs Waived From Drug Pricing Bill, Finance Chair Vows

Sept. 24, 2021, 4:57 PM

A Senate leader crafting a drug pricing proposal is trying to win the support of centrist Democrats by promising to carve out exceptions for small biotech companies.

Those moderate senators are warning they won’t commit until they see all the details.

Ron Wyden (D-Ore.), chairman of the Senate Finance Committee, said he’s promised that pharmaceutical companies with limited access to capital or that invest heavily in research could be exempt from central parts of his drug pricing bill, which he has yet to unveil completely. He outlined the components of the measure in June but has yet to release legislative …

Source link


Share on facebook
Share on twitter
Share on pinterest
Oliver Bolt

Oliver Bolt

On Key

Related Posts

Evergrande’s troubles loom over global markets

Read a transcript of this episode on Global financial markets are jittery about the possible default of indebted